JP2022544825A5 - - Google Patents

Info

Publication number
JP2022544825A5
JP2022544825A5 JP2022510857A JP2022510857A JP2022544825A5 JP 2022544825 A5 JP2022544825 A5 JP 2022544825A5 JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022544825 A5 JP2022544825 A5 JP 2022544825A5
Authority
JP
Japan
Application number
JP2022510857A
Other languages
Japanese (ja)
Other versions
JP2022544825A (ja
JPWO2021035054A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047202 external-priority patent/WO2021035054A1/en
Publication of JP2022544825A publication Critical patent/JP2022544825A/ja
Publication of JPWO2021035054A5 publication Critical patent/JPWO2021035054A5/ja
Publication of JP2022544825A5 publication Critical patent/JP2022544825A5/ja
Pending legal-status Critical Current

Links

JP2022510857A 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン Pending JP2022544825A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962889338P 2019-08-20 2019-08-20
US62/889,338 2019-08-20
US202063061070P 2020-08-04 2020-08-04
US63/061,070 2020-08-04
PCT/US2020/047202 WO2021035054A1 (en) 2019-08-20 2020-08-20 Lymphodepletion dosing regimens for cellular immunotherapies

Publications (3)

Publication Number Publication Date
JP2022544825A JP2022544825A (ja) 2022-10-21
JPWO2021035054A5 JPWO2021035054A5 (https=) 2023-08-29
JP2022544825A5 true JP2022544825A5 (https=) 2023-08-29

Family

ID=72291163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510857A Pending JP2022544825A (ja) 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン

Country Status (6)

Country Link
US (1) US20220273720A1 (https=)
EP (1) EP4017526A1 (https=)
JP (1) JP2022544825A (https=)
AU (1) AU2020333851A1 (https=)
CA (1) CA3148179A1 (https=)
WO (1) WO2021035054A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
KR20240032732A (ko) * 2021-05-13 2024-03-12 엔카르타, 인크. 암 면역요법을 위한 투약 요법
CA3219473A1 (en) * 2021-05-24 2022-12-01 Francisco Leon Methods for treating post infectious autoimmune diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250009800A1 (en) * 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20250041417A1 (en) * 2021-12-10 2025-02-06 Precision Biosciences, Inc. Methods for cancer immunotherapy
AU2024337370A1 (en) * 2023-09-08 2026-02-26 Fate Therapeutics, Inc. Ipsc-derived effector cells for autoimmune disease treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
DE69534629D1 (de) 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
ATE524545T1 (de) 1994-08-20 2011-09-15 Gendaq Ltd Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗cd3抗体およびその使用方法
AU2006272634B2 (en) 2005-07-26 2013-01-24 Sangamo Therapeutics, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
EP2694089B1 (en) 2011-04-05 2024-06-05 Cellectis New tale-protein scaffolds and uses thereof
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2013158256A2 (en) 2012-04-20 2013-10-24 Angimmune, Llc Immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 t 세포의 조작 방법
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP6346266B2 (ja) 2013-03-21 2018-06-20 サンガモ セラピューティクス, インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
US10000746B2 (en) 2013-05-31 2018-06-19 Cellectis LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
CN117070468A (zh) 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
IL264502B2 (en) 2016-08-29 2023-09-01 Tiziana Life Sciences Plc Anti-cd3 antibody formulations
ES2925644T3 (es) 2016-10-04 2022-10-19 Prec Biosciences Inc Dominios coestimuladores para su uso en células modificadas genéticamente
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
EP4069285A1 (en) * 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)